Stem Cell Therapy Eases Crohn’s Disease by Blocking Iron-Driven Cell Death

Crohn’s disease is one of the most stubborn forms of inflammatory bowel disease, marked by chronic inflammation of the right colon and terminal ileum that brings diarrhea, abdominal pain, and sometimes life-threatening intestinal obstruction. Roughly twelve percent of patients carry a genetic predisposition, with certain populations showing heightened risk, and although corticosteroids, thiopurines, biologics, and even fecal microbiota transplantation are used to manage symptoms, no cure exists. Against this backdrop, a new study published in Immunity, Inflammation and Disease offers an intriguing mechanistic explanation for why mesenchymal stem cells, which have already shown promise in healing perianal fistulas in Crohn’s patients, can quiet intestinal inflammation: by switching off a form of iron-dependent cell death known as ferroptosis through regulation of a single metabolic enzyme.

Mesenchymal stem cells, or MSCs, are multipotent progenitor cells that can be isolated from bone marrow, umbilical cord, adipose tissue, and amniotic fluid. Their therapeutic reputation rests largely on immunomodulation. Through paracrine signaling and direct contact with immune cells, they release growth factors and cytokines that promote angiogenesis, prevent fibrosis, and restrain the proliferation of macrophages, dendritic cells, natural killer cells, B cells, and T cells by arresting those cells in the G0/G1 phase of the cell cycle. What has remained murky is precisely how these properties translate into benefit inside an inflamed gut. The new work points to a metabolic route involving cystathionine-β-synthase, or CBS, the rate-limiting enzyme of the transsulfuration pathway.

Ferroptosis is a recently characterized mode of regulated cell death that depends on iron and is driven by unchecked lipid peroxidation. It emerges when the system xc⁻–glutathione–GPX4 antioxidant axis fails, leaving lipid hydroperoxides to accumulate in cell membranes. Cysteine, the rate-limiting precursor of glutathione synthesis, sits at the heart of this defense, and when cysteine is scarce, cells can manufacture it from methionine via the transsulfuration pathway, with CBS as the gatekeeper. Previous studies have linked ferroptosis directly to Crohn’s disease: patients show elevated lipid hydroperoxides and impaired GPX4 activity in small intestinal epithelial cells, and blocking ferroptosis reduces disease severity in mouse models. MSCs, meanwhile, have been shown to prevent ferroptosis in spinal cord and liver injuries, and earlier work by the same team demonstrated benefit in colitis.

To identify which molecular players mattered most, the researchers turned to bioinformatics. Mining the GEO database, they assembled a training dataset of 196 inflamed ileal samples from Crohn’s patients and 25 healthy ileal biopsies, plus a validation set of 65 patient mucosa samples and 12 healthy controls. Crossing differentially expressed genes with 396 ferroptosis-related genes from the FerrDb database yielded 25 ferroptosis-related differentially expressed genes, 19 of them upregulated and 6 downregulated. Three machine learning algorithms—LASSO, support vector machine recursive feature elimination, and random forest—were then deployed in parallel to nominate hub genes. CBS surfaced as the consensus hit, appearing among the top five candidates from every method. Critically, this ferroptosis-inhibiting gene was consistently downregulated in Crohn’s samples, with an area under the receiver operating characteristic curve of 0.936 in the training set and 0.942 in the validation set, figures that mark CBS as a remarkably strong diagnostic marker.

The bioinformatics claims did not stay confined to datasets. Working with pathological sections from 25 Crohn’s patients and 25 matched controls at the First Affiliated Hospital of Guangxi Medical University, the team performed immunohistochemistry and found that CBS, which localizes predominantly in the cytoplasm, was expressed at significantly lower levels in the colonic tissue of patients than in healthy individuals. This clinical confirmation aligned neatly with the machine learning results and set the stage for the animal experiments that would test whether stem cells could restore the missing signal.

Using the trinitrobenzene sulfonic acid model, a standard stand-in for Crohn’s-like colitis, the researchers sensitized female BALB/c mice and induced colitis by enema. The mice lost weight and developed elevated disease activity scores, confirming successful model establishment. A treatment group then received one million bone marrow-derived MSCs intraperitoneally on days one, three, and five. The effect was striking: treated mice showed markedly improved weight retention, lower disease activity index scores, fewer and smaller ulcers, and reduced macroscopic colon damage. At the molecular level, the anti-inflammatory cytokine IL-10 rose while the pro-inflammatory cytokine TNF-α fell. Blinded outcome assessment throughout the experiment strengthened confidence in these results.

The ferroptosis connection emerged when the team examined biochemical markers in colon tissue. Colitic mice carried elevated levels of malondialdehyde, a lipid peroxidation end product, and excess iron, both hallmarks of ferroptotic stress. After MSC treatment, these markers dropped significantly. Gene and protein analyses told the same story: mRNA and protein levels of GPX4, SLC7A11, and ferritin heavy chain 1, all central to the cellular antioxidant and iron-storage machinery, were depressed in the model group and restored by stem cell therapy. Immunohistochemistry showed GPX4 staining, concentrated in the cytoplasm, expanding after treatment. In short, the antioxidant defense that ferroptosis had disabled was switched back on.

The pivotal question was whether this rescue ran through CBS.MSC treatment significantly increased CBS mRNA and protein expression in colonic tissue, along with glutathione levels, and immunohistochemistry confirmed greater CBS-positive area in the cytoplasm of treated mice. To test causality, the researchers added aminooxyacetic acid, a well-established CBS inhibitor, to the stem cell regimen. The combination reversed nearly every benefit: mice given both the inhibitor and MSCs lost more weight, scored worse on disease activity, showed higher TNF-α and lower IL-10, suffered more severe ulceration, and displayed lower protein levels of CBS, SLC7A11, FTH1, and GPX4 than mice receiving stem cells alone. Glutathione fell while malondialdehyde and iron climbed, and CBS expression in the inhibitor group was no better than in untreated colitic mice. The conclusion was difficult to escape: MSCs alleviate colitis by upregulating CBS, stimulating cysteine synthesis through the transsulfuration pathway, replenishing glutathione and GPX4, and thereby extinguishing ferroptosis.

The authors are candid about the limits of the work. The TNBS model, though widely used, does not fully reproduce the chronic, relapsing, immunologically heterogeneous nature of human Crohn’s disease. Pharmacological inhibition of CBS with AOAA, while suggestive, is less definitive than genetic knockdown or knockout approaches would be. And although a battery of ferroptosis markers was assessed, direct ultrastructural evidence—such as the mitochondrial shrinkage and cristae loss visible by transmission electron microscopy—was not obtained. Future studies, the team suggests, should test clinical-grade MSCs in larger models and organoid systems, manipulate CBS genetically to confirm the causal chain, and apply single-cell RNA sequencing with spatial transcriptomics to map how stem cells communicate with epithelial and immune cells in the ferroptosis-regulated gut.

Even with those caveats, the study delivers a compelling synthesis: a machine-learned diagnostic gene, validated in human tissue, connected mechanistically to a stem cell therapy in vivo. By demonstrating that mesenchymal stem cells upregulate CBS, restore the antioxidant system, and inhibit ferroptosis to reduce inflammation, the researchers offer a new theoretical framework for Crohn’s pathogenesis and a concrete therapeutic target. If subsequent studies confirm the CBS–ferroptosis axis in patients, targeting this pathway—whether with stem cells or with drugs that mimic their effect—could open a genuinely novel front in the treatment of inflammatory bowel disease.

Subject of Research: Mesenchymal stem cell therapy for Crohn's disease through regulation of CBS-mediated ferroptosis

Article Title: Mesenchymal Stem Cells Alleviate Crohn's Disease by Regulating CBS‐Mediated Ferroptosis

Article References: Huang, Z., Xu, X., Huang, Z., Han, B., Jiang, D., Lv, X., Huang, Z., Lin, G., Huang, F., Li, Y., Han, L., Chen, D., Lin, J., & Lv, X. (2026). Mesenchymal Stem Cells Alleviate Crohn's Disease by Regulating CBS‐Mediated Ferroptosis. Immunity, Inflammation and Disease, 14(9), Article e70506. https://doi.org/10.1002/iid3.70506

Image Credits: AI Generated

DOI: 10.1002/iid3.70506

Keywords: Crohn's disease, mesenchymal stem cells, ferroptosis, cystathionine-β-synthase, GPX4, glutathione, inflammatory bowel disease, TNBS colitis model, transsulfuration pathway, machine learning biomarkers, immunomodulation, lipid peroxidation